Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tony Look into my eye's look deeply into my eyes ~~~You are now under my power you will Merg with Big Pharma, Merg Tony !! Merrrrrrrrrrrggggggggg when I click my mouse you will remember nothing.
All eyes are on you Tony, come on !! I think Retinome {TM} will bring in the $$$$$$$
Whats you got cooking Tony ? Something Good
Dnap a great comp. to invest in - why cause i said so.LOL
It will be a good year, you will see, be happy and dont get down. It just the wind blowing away the chaf.
Rocks, lots and lots of Rocks here, ground way to hard, needs rain, dont know even rain may not help.
From the Wall Street Transcript July 2003 - " So we will, may very well work our way up to 100 people within the next year or two and most of that will be in addition to scientific staff so more work can be done faster."
*************************************************************
A 100 people ???? !!!! In a year !!! Thats July of 2004 !!! Not to far away.What could it mean ????? Keep your eyes and ears open folks.
Tony come on with the eyes will ya.Spend some of that money you got and hire a dam good programmer and send that grad kid back to school.Spend the money get some one with 15 years of exp.
One other thing about Ovarian I believe its tied into the Orchid deal where Statnome is not.Therefore more money to go with Statnome.
Stockholder, yes Clinical testing will always be a Major and primany consideration Day to day.But without the patent approval and FDA approval it will never go to market, if it did it would be shot down so fast it would make your head spin and we would all lose. Big investors are looking for this, its inc. for their investment.All the Clinical Trials that Tony is doing is toward that end.As for Ovanome I think its been put on the back burner based on what Tony has said about one before the other and because Ovanome is no where to be found at the Patent office and the FDA web site. BUT that doesn't mean Cliinical trials are still not going on. In Fact they are, its just Statnome is in the system where Ovanome is not.Either way we will do very very well.
Last update on Statnome at the patent office,statnome was at step 13 in Aug. of 2003. Thats 5 mo.'s ago. Figure 3 of the Mo.'s went through 2 steps and 2 of the Mo.'s went through 1 step, Hay thats fair based on its history.That puts us around step 21 in Feb. 2004, of about 45 to 55 Steps needed to complete approval on the patent.With a little luck patent approval on Statnome in or around Jan or Feb 2005.Hay its not the FDA approval I know but Getting News Out that DNAP has a patent approval on Statnome, well what do you think will happen at that point ? HA, Ba Ha hahahahahah We go to the Moon Thats what.
kgarner,nice you might have something there. Keep on praying
Oh to much fun - Got to run - all this joking around - not good for me old ticker - Think i'll just up and kick the bucket. LOL Ya, ok, i cant take anymore good night you animals.
up up and away with my beautiful my beautiful Dnap.
Go Dnap, Go Tony
Ask someone at Dnap. If he is they will say ,yes. But if he's not,they will not say yes or no.LOL
gunnabeoneday,I hope so !! Its not good if he's not,so soon after the others left.
0014] By way of example, a method of the invention allows an inference to be drawn that a nucleic acid sample is that of a human Caucasian having a particular eye color or eye shade. In one aspect, a method of inferring that a sample is that of a Caucasian having a particular eye color or eye shade is performed by identifying a penetrant pigmentation-related haplotype allele, including at least one of a) nucleotides of the DCT gene corresponding to a DCT-A haplotype, which includes nucleotide 609 of SEQ ID NO: 1 [702], nucleotide 501 of SEQ ID NO:2 [650], and nucleotide 256 of SEQ ID NO:3 [marker 675]; b) nucleotides of the MC1R gene corresponding to a melanocortin-1 receptor (MC1R)-A haplotype, which includes nucleotide 442 of SEQ ID NO:4 [217438], nucleotide 619 of SEQ ID NO:5 [217439], and nucleotide 646 of SEQ ID NO:6 [217441]; c) nucleotides of the OCA2 gene, corresponding to an OCA2-A haplotype, which includes nucleotide 135 of SEQ ID NO:7 [217458], nucleotide 193 of SEQ ID NO:8 [886894], nucleotide 228 of SEQ ID NO:9 [marker 886895], and nucleotide 245 of SEQ ID NO: 10 [marker 886896]; d) nucleotides of the OCA2 gene, corresponding to an OCA2-B haplotype, which includes nucleotide 189 of SEQ ID NO: 11 [marker 217452]], nucleotide 573 of SEQ ID NO: 12 [marker 712052], and nucleotide 245 of SEQ ID NO: 13 [marker 886994]; e) nucleotides of the OCA2 gene, corresponding to an OCA2-C haplotype, which includes nucleotide 643 of SEQ ID NO:14 [712057], nucleotide 539 of SEQ ID NO:15 [712058], nucleotide 418 of SEQ ID NO:16 [712060], and nucleotide 795 of SEQ ID NO:17, [712064]; f) nucleotides of the OCA2 gene, corresponding to an OCA2-D haplotype, which includes nucleotide 535 of SEQ ID NO: 18, [712054], nucleotide 554 of SEQ ID NO:19, [712056], and nucleotide 210 of SEQ ID NO:20, [886892]; g) nucleotides of the OCA2 gene, corresponding to an OCA2-E haplotype, which includes nucleotide 225 of SEQ ID NO:21, [217455], nucleotide 170 of SEQ ID NO:22, [712061], and nucleotide 210 of SEQ ID NO:20, [886892]; h) nucleotides of the TYRP1 gene corresponding to a TYRP1-B haplotype which includes nucleotide 172 of SEQ ID NO:23, [886938], or nucleotide 216 of SEQ ID NO:24; [886943], or any combination of the above listed penetrant haplotypes. For example, the pigmentation-related haplotype allele of MC1R-A can be CCC; the pigmentation-related haplotype allele of OCA2-A can be TTA, CCAG, or TTAG; the pigmentation-related haplotype allele of OCA2-B can be CAA, CGA, CAC, or CGC; the pigmentation-related haplotype allele of OCA2-C can be GGAA, TGAA, or TAAA; the pigmentation-related haplotype allele of OCA2-D can be AGG or GGG; the pigmentation-related haplotype allele of OCA2-E can be GCA; the pigmentation-related haplotype allele of TYRP1-B can be TC; and the pigmentation-related haplotype allele of DCT-A can be CTG or GTG.
[0015] An inference that a nucleic acid sample is that of a human Caucasian having a particular eye color or eye shade can be strengthened by further identifying in the nucleic acid sample at least one nucleotide occurrence of a latent pigmentation-related SNP of a pigmentation gene, wherein the latent pigmentation-related SNP is nucleotide 61 of SEQ ID NO:25 [marker 560], nucleotide 201 of SEQ ID NO:26 [marker 552], nucleotide 201 of SEQ ID NO:27 [marker 559], nucleotide 201 of SEQ ID NO:28 [marker 468], nucleotide 657 of SEQ ID NO:29 [marker 657], nucleotide 599 of SEQ ID NO:30 [marker 674], nucleotide 267 of SEQ ID NO:31 [marker 632], nucleotide 61 of SEQ ID NO:32 [marker 701], nucleotide 451 of SEQ ID NO:33 [marker 710]; nucleotide 326 of SEQ ID NO:34 [marker 217456], nucleotide 61 of SEQ ID NO:35 [marker 656], nucleotide 61 of SEQ ID NO:36, nucleotide 61 of SEQ ID NO:37 [marker 637], nucleotide 93 of SEQ ID NO:38 [marker 278], nucleotide 114 of SEQ ID NO:39 [marker 386], nucleotide 558 of SEQ ID NO:40 [marker 217480], nucleotide 221 of SEQ ID NO:41 [marker 951497], nucleotide 660 of SEQ ID NO:42 [marker 217468], nucleotide 163 of SEQ ID NO:43 [marker 217473], nucleotide 364 of SEQ ID NO:44 [marker 217485], nucleotide 473 of SEQ ID NO:45 [marker 217486], nucleotide 314 of SEQ ID NO:46 [marker 869787], nucleotide 224 of SEQ ID NO:47 [marker 869745], nucleotide 169 of SEQ ID NO:48 [marker 886933], nucleotide 214 of SEQ ID NO:49 [marker 886937], or nucleotide 903 of SEQ ID NO:50; [886942], or a combination of the above listed pigmentation-related SNPs. Similarly, the inference can be strengthened by further identifying in the nucleic acid sample at least one latent pigmentation-related haplotype allele of a pigmentation gene, wherein the latent pigmentation-related haplotype allele includes a) nucleotides of the ASIP gene corresponding to an ASIP-A haplotype, which include nucleotide 201 of SEQ ID NO:26 [marker 552], and nucleotide 201 of SEQ ID NO:28 [marker 468]; b) nucleotides of the DCT gene corresponding to a DCT-B haplotype, which include nucleotide 451 of SEQ ID NO:33 [marker 710], and nucleotide 657 of SEQ ID NO:29 [marker 657]; c) nucleotides of the SILV gene corresponding to a SILV-A haplotype, which includes nucleotide 61 of SEQ ID NO:35 [marker 656], and nucleotide 61 of SEQ ID NO:36; d) nucleotides of the TYR gene corresponding to a TYR-A haplotype, which includes nucleotide 93 of SEQ ID NO:38 [marker 278], and nucleotide 114 of SEQ ID NO:39 [marker 386]; e) nucleotides of the TYRP1 gene corresponding to a TYRP1-A haplotype, which include nucleotide 364 of SEQ ID NO:44 [marker 217485], nucleotide 169 of SEQ ID NO:48 [marker 886933], or nucleotide 214 of SEQ ID NO:49 [marker 886937], or any combination of the above listed latent pigmentation-related haplotypes. For example, the latent pigmentation-related haplotype allele of ASIP-A can be GT, AT; the latent pigmentation-related haplotype allele of DCT-B can be TA, TG; the latent pigmentation-related haplotype allele of SILV-A can be TC, TT; or CC the latent pigmentation-related haplotype allele of TYR-A can be GA, AA, or GG; and the latent pigmentation-related haplotype allele of TYRP1-A can be GTG, TTG, or GTT.
[0016] A method of identifying a pigmentation related SNP, including a pigmentation related haplotype allele can be performed using any method useful for identifying a particular nucleotide at a specific position in a nucleotide sequence or, where the nucleotide sequence encodes an amino acid sequence, by identifying an amino acid encoded by a codon of the nucleotide sequence, provided the nucleotide occurrences of the SNP result in a codons that encode different amino acids. Particularly useful methods include those that are readily adaptable to a high throughput format, to a multiplex format, or to both. In addition, a method of the invention can further include applying information relating to the pigment-related haplotype alleles to a matrix created using a feature modeling algorithm. For example, the feature modeling algorithm can be quadratic classifier or can perform a correspondence analysis.
[0017] Methods for detecting a nucleotide change can utilize one or more oligonucleotide probes or primers, including, for example, an amplification primer pair, that selectively hybridize to a target polynucleotide, which contains one or more pigmentation-related SNP positions. Oligonucleotide probes useful in practicing a method of the invention can include, for example, an oligonucleotide that is complementary to and spans a portion of the target polynucleotide, including the position of the SNP, wherein the presence of a specific nucleotide at the position (i.e., the SNP) is detected by the presence or absence of selective hybridization of the probe. Such a method can further include contacting the target polynucleotide and hybridized oligonucleotide with an endonuclease, and detecting the presence or absence of a cleavage product of the probe, depending on whether the nucleotide occurrence at the SNP site is complementary to the corresponding nucleotide of the probe. A pair of probes that specifically hybridize upstream and adjacent and downstream and adjacent to the site of the SNP, wherein one of the probes includes a nucleotide complementary to a nucleotide occurrence of the SNP, also can be used in an oligonucleotide ligation assay, wherein the presence or absence of a ligation product is indicative of the nucleotide occurrence at the SNP site. An oligonucleotide also can be useful as a primer, for example, for a primer extension reaction, wherein the product (or absence of a product) of the extension reaction is indicative of the nucleotide occurrence. In addition, a primer pair useful for amplifying a portion of the target polynucleotide including the SNP site can be useful, wherein the amplification product is examined to determine the nucleotide occurrence at the SNP site.
[0018] Where the particular nucleotide occurrence of a SNP, or nucleotide occurrences of a pigmentation-related haplotype, is such that the nucleotide occurrence results in an amino acid change in an encoded polypeptide, the nucleotide occurrence can be identified indirectly by detecting the particular amino acid in the polypeptide. The method for determining the amino acid will depend, for example, on the structure of the polypeptide or on the position of the amino acid in the polypeptide. Where the polypeptide contains only a single occurrence of an amino acid encoded by the particular SNP, the polypeptide can be examined for the presence or absence of the amino acid. For example, where the amino acid is at or near the amino terminus or the carboxy terminus of the polypeptide, simple sequencing of the terminal amino acids can be performed. Alternatively, the polypeptide can be treated with one or more enzymes and a peptide fragment containing the amino acid position of interest can be examined, for example, by sequencing the peptide, or by detecting a particular migration of the peptide following electrophoresis. Where the particular amino acid comprises an epitope of the polypeptide, the specific binding, or absence thereof, of an antibody specific for the epitope can be detected. Other methods for detecting a particular amino acid in a polypeptide or peptide fragment thereof are well known and can be selected based, for example, on convenience or availability of equipment such as a mass spectrometer, capillary electrophoresis system, magnetic resonance imaging equipment, and the like.
[0019] In another embodiment, a method of the invention allows an inference to be drawn as to hair color or hair shade of a human subject by identifying in a nucleic acid sample of the subject a penetrant pigmentation-related haplotype allele in at least one pigmentation gene, for example, in at least one of OCA2, ASIP, TYRP1, or MC1R. For example, an inference can be drawn as to the hair color or hair shade of a human by identifying in a nucleic sample from the human a penetrant pigmentation-related haplotype allele, including in at least one of a) nucleotides of the ASIP gene corresponding to an ASIP-B haplotype, which include nucleotide 202 of SEQ ID NO:27, [559], and nucleotide 61 of SEQ ID NO:25, [560]; b) nucleotides of the MC1R gene corresponding to an MC1R-A haplotype, which include nucleotide 442 of SEQ ID NO:4 [217438], nucleotide 619 of SEQ ID NO:5 [217439], and, nucleotide 646 of SEQ ID NO:6 [217441]; c) nucleotides of the OCA2 gene corresponding to an OCA2-G haplotype, which include nucleotide 418 of SEQ ID NO: 16 [712060], nucleotide 210 of SEQ ID NO:20, [886892], and nucleotide 245 of SEQ ID NO: 10 [marker 886896]; d) nucleotides of the OCA2 gene corresponding to a OCA2-H haplotype, which include nucleotide 225 of SEQ ID NO:21, [217455], nucleotide 643 of SEQ ID NO:14 [712057], and nucleotide 193 of SEQ ID NO:8 [886894]; e) nucleotides of the OCA2 gene corresponding to a OCA2-I haplotype, which include nucleotide 135 of SEQ ID NO:7 [217458], and nucleotide 554 of SEQ ID NO:19, [712056]; f) nucleotides of the OCA2 gene corresponding to a OCA2-J haplotype, which include nucleotide 535 of SEQ ID NO:18, [712054], and nucleotide 228 of SEQ ID NO:9 [marker 886895]; or g) nucleotides of the TYRP1 gene corresponding to a TYRP1-C haplotype, which include nucleotide 473 of SEQ ID NO:45, [217486], or, nucleotide 214 of SEQ ID NO:49; [886937], or any combination of the above-listed penetrant pigmentation-related haplotypes.
SUMMARY OF THE INVENTION
[0009] The present invention relates to methods for inferring a genetic pigmentation trait of a human subject from a nucleic acid sample or a polypeptide sample of the subject, and compositions for practicing such methods. The methods of the invention are based, in part, on the identification of single nucleotide polymorphisms (SNPs) that, alone or in combination, allow an inference to be drawn as to a genetic pigmentation trait such as hair shade, hair color, eye shade, or eye color, and further allow an inference to be drawn as to race. As such, the compositions and methods of the invention are useful, for example, as forensic tools for obtaining information relating to physical characteristics of a potential crime victim or a perpetrator of a crime from a nucleic acid sample present at a crime scene, and as tools to assist in breeding domesticated animals, livestock, and the like to contain a pigmentation trait as desired.
[0010] A method of the invention can be performed, for example, by identifying in a nucleic acid sample at least one pigmentation-related haplotype allele of at least one pigmentation gene, wherein the pigmentation gene is oculocutaneous albinism II (OCA2), agouti signaling protein (ASIP), tyrosinase-related protein 1 (TYRP1), tyrosinase (TYR), adaptor-related protein complex 3, beta 1 subunit (AP3B1) (also known as adaptin B 1 protein (ADP1)), adaptin 3 D subunit 1 (AP3D1), dopachrome tautomerase (DCT), silver homolog (SILV), AIM-1 protein (LOC51151), proopiomelanocortin (POMC), ocular albinism 1 (OA 1), microphthalmia-associated transcription factor (MITF), myosin VA (MYO5A), RAB27A, coagulation factor II (thrombin) receptor-like 1 (F2RL1), or Adaptin 3 D subunit 1 (AP3D 1) whereby the haplotype allele is associated with the pigmentation trait, thereby inferring the genetic pigmentation trait of the subject. In one embodiment, the pigmentation gene includes at least one of OCA2, ASIP, TYRP1, TYR, SILV AP3B 1, AP3D1, AP3D1, or DCT, and the pigmentation-related haplotype allele is a penetrant pigmentation-related haplotype allele, which allows an inference to be drawn as to a pigmentation trait of a subject from which the nucleic acid sample was obtained. For example, where the genetic pigmentation trait is eye shade, a pigmentation-related haplotype allele can be identified in at least one of the OCA2, TYRP1, or DCT gene.
[0011] A genetic pigmentation trait that can be inferred according to a method of the invention can be hair color, hair shade, eye color, or eye shade, or can be race. A pigmentation-related haplotype allele includes specific nucleotide occurrences of two or more SNPs in a sequence of a pigmentation gene, particularly specific nucleotide occurrences of SNPs, which can be present and the same or different in one or both alleles of the pigmentation gene. A penetrant pigmentation-related haplotype allele is one that, by itself, allows an inference to be drawn that a genetic pigmentation trait of a human subject is more likely than random. A latent pigmentation-related haplotype allele is one that, in the context of one or more penetrant, or other latent haplotypes, allows a stronger inference to be drawn than the inference due to the penetrant or other latent haplotype allele(s), alone.
[0012] A sample useful for practicing a method of the invention can be any biological sample of a subject that contains nucleic acid molecules, including portions of the gene sequences to be examined, or corresponding encoded polypeptides, depending on the particular method. As such, the sample can be a cell, tissue or organ sample, or can be a sample of a biological fluid such as semen, saliva, blood, and the like. A nucleic acid sample useful for practicing a method of the invention will depend, in part, on whether the SNPs of the haplotype to be identified are in coding regions or in non-coding regions. Thus, where at least one of the SNPs to be identified is in a non-coding region, the nucleic acid sample generally is a deoxyribonucleic acid (DNA) sample, particularly genomic DNA or an amplification product thereof. However, where heteronuclear ribonucleic acid (RNA), which includes unspliced mRNA precursor RNA molecules, is available, a cDNA or amplification product thereof can be used. Where the each of the SNPs of the haplotype is present in a coding region of the pigmentation gene(s), the nucleic acid sample can be DNA or RNA, or products derived therefrom, for example, amplification products. Furthermore, while the methods of the invention generally are exemplified with respect to a nucleic acid sample, it will be recognized that particular haplotype alleles can be in coding regions of a gene and can result in polypeptides containing different amino acids at the positions corresponding to the SNPs due to non-degenerate codon changes. As such, in another aspect, the methods of the invention can be practiced using a sample containing polypeptides of the subject.
[0013] As disclosed herein, the identification of at least one penetrant pigmentation-related haplotype allele of at least one pigmentation gene allows an inference to be drawn as to a genetic pigmentation trait of a human subject. An inference drawn according to a method of the invention can be strengthened by identifying a second, third, fourth or more penetrant pigmentation related haplotype alleles and/or one or more latent pigmentation related haplotype alleles in the same pigmentation gene or in one or more other pigmentation genes. Accordingly, in another embodiment, a method of the invention can further include identifying in the nucleic acid sample at least a second penetrant pigmentation related haplotype allele of the first pigmentation gene and/or at least one penetrant pigmentation-related haplotype allele of at least a second pigmentation gene, for example, of an OCA2, ASIP, TYRP1, TYR, AP3B1, AP3D1, DCT, SILV, LOC51151, AIM1, POMC, OA1, MITF, MYOSA, RAB27A, F2RL1, AP3D1, or melanocortin-1 receptor (MC1R) gene.
[0004] 2. Background Information
[0005] Biotechnology has revolutionized the field of forensics. More specifically, the identification of polymorphic regions in human genomic DNA has provided a means to distinguish individuals based on the occurrence of a particular nucleotide at each of several positions in the genomic DNA that are known to contain polymorphisms. As such, analysis of DNA from an individual allows a genetic fingerprint or "bar code" to be constructed that, with the possible exception of identical twins, essentially is unique to one particular individual in the entire human population.
[0006] In combination with DNA amplification methods, which allow a large amount of DNA to be prepared from a sample as small as a spot of blood or semen or a hair follicle, DNA analysis has become a routine tool in criminal cases as evidence that can free or, in some cases, convict a suspect. Indeed, criminal courts, which do not yet allow the results of a lie detector test into evidence, admit DNA evidence into trial. In addition, DNA extracted from evidence that, in some cases, has been preserved for years after the crime was committed, has resulted in the convictions of many people being overturned.
[0007] Although DNA fingerprint analysis has greatly advanced the field of forensics, and has resulted in freedom of people, who, in some cases, were erroneously imprisoned for years, current DNA analysis methods are limited. In particular, DNA fingerprinting analysis only provides confirmatory evidence that a particular person is, or is not, the person from which the sample was derived. For example, while DNA in a semen sample can be used to obtain a specific "bar code", it provides no information about the person that left the sample. Instead, the bar code can only be compared to the bar code of a suspect in the crime. If the bar codes match, then it can reasonably be concluded that the person likely is the source of the semen. However, if there is not a match, the investigation must continue.
[0008] An effort has begun to accumulate a database of bar codes, particularly of convicted criminals. Such a database allows prospective use of a bar code obtained from a biological sample left at a crime scene; i.e., the bar code of the sample can be compared, using computerized methods, to the bar codes in the database and, where the sample is that of a person whose bar code is in the database, a match can be obtained, thus identifying the person as the likely source of the sample from the crime scene. While the availability of such a database provides a significant advance in forensic analysis, the potential of DNA analysis is still limited by the requirement that the database must include information relating to the person who left the biological sample at the crime scene, and it likely will be a long time, if ever, that such a database will provide information of an entire population. Thus, there is a need for methods that can provide prospective information about a subject from a nucleic acid sample of the subject. The invention satisfies this need, and provides additional advantages.
Stockboy,great example.Thanks,we will win on this one.
If you got 5 different things wrong with a car are you going to send it to 5 different places I dont think so, you will send it to where all the work can be done right there. Your not going to generate 5 different PO's # are you ? Come on be real. Dnap can do standard DNA work as well as the rest, come on get real.
Phenome(tm) Snip database. We have mined SNP data from publicly available human genome data and our own private experiments. Our work here has focused on expounding on the complexity of genetic variation within certain key genes across entire populations as opposed to cataloguing variance for virtually all genes (including unimportant and unconserved genes) of a few people. (In case you are wondering, expounding on variation within all genes across entire populations is economically infeasible). Our Phenome database is focused on the genes that decades of literature have shown are important for those traits of most viable economical status (such as drug metabolism or developmental relevance for cancer predisposition). The database is stratified for over 30 qualitative and quantitative phenotypic variables to enable us to design intelligent SNP arrays well-suited for the particular questions we are asking. Only two other companies possess a database like ours, but neither is searchable like ours.
FEMS. The company has developed a Front-End Management System (FEMS) software product to manage the workflow of DNA through automated DNA analysis equipment. The work load going into this equipment (front-end to the machine) is a rate-limiting step for high-throughput operation. Before the development of FEMS, many hours were wasted by DNA technicians as they program the equipment for operation. Our software automates this tedious process. FEMS enables the auto-generation of DNA template identification numbers, establishes a DNA template physical archive system, creates a database for the archival of template annotation data, enables bar-code retrieval of DNA from an archive database, and enables the automated loading of DNA template annotation into the operating software of DNA sequencing and DNA profiling machines. It will be easily adaptable to the MassArray or GBA SNP genotyping systems. These tasks are critical to managing the tremendous amount of data that is inherent to DNA work.
TRUSpin(tm) - a patent-pending, multi-well, reusable spin column tool by which to purify DNA sequencing reactions and DNA profiles. TruSpin(tm) eliminates the primer and unincorporated nucleotide peaks which commonly disrupt data analysis during DNA sequencing or STR profiling. Current tools available on the market use disposable plastic parts and resin bed heights that are unsuitable for efficient DNA purification. The TruSpin(tm) product enable superior purification in a reusable format through patent-pending design parameters and protocol development. This product will be used to reduce the overhead costs associated with producing an SNP profile. It will also be licensed out for use in non-SNP and non-STR applications to bring annual revenues to the company.
SNIPScan(tm) - is a patent-pending variation of TruSeq(tm) that is optimized for application to DNA testing (STR and SNP profiling). DNA testing is accomplished using the same enzyme and basic reagents as DNA sequencing, but a different amplification strategy (geometric vs. linear) and primers. DNA testing is more expensive than DNA sequencing, and as DNA testing increases in the future, this product has even more potential than TruSeq(tm).
TRUSEQ(tm).This patent-pending product was developed at GAFF biologic (the Company's predecessor). It is a molecular biology reagent that is added to thermocycle enzyme reactions which form the basis for automated DNA cycle sequencing reactions, STR profiling reactions and SNP profiling extension reactions. The product enables a scientist to dilute expensive analytical reagents used during these processes and perform their reactions in a much more economical manner. For example, a DNA researcher currently adds 8 microliters of BigDye Terminator (BDT) Sequencing Mix (containing DNA sequencing enzyme) to each sequencing reaction, which costs $8 per reaction (each BDT kit costs $800 and is good for 100 reactions). If the researcher attempts to use less, the quality of the DNA sequencing results are generally unacceptable (low peak height, short read length or no read at all). However, TruSeq(tm) allows kit reagent dilution by stabilizing the main ingredient of the BDT Sequencing Mix (AmpliTaq DNA Polymerase FS's) in the reaction tube. The sequencer can dilute the bdt sequencing mix 0.5/ 4.4 in TruSeq(tm), and get the same results as if they used undiluted BDT Sequencing Mix. In essence, the DNA sequencer can add one half a microliter of sequencing chemicals to the reaction instead of 8 microliters, saving $7.50 per reaction. Extensive study at our laboratory show that the sequencing results obtained by using TruSeq(tm) are indistinguishable from the undiluted and more expensive reaction set up in every way. A specific cycling protocol is required for use of TruSeq(tm). The product has been independently validated by scientists at Life Technologies of Rockville MD, a company currently negotiating with the Company for the worldwide marketing and distribution rights to the product for non-STR and non-SNP applications. Market research has revealed a 10% market share in the DNA sequencing community would translate into over 2 million dollars of net profit for the company. The product is a purple liquid, encapsulated in a sterile sample vial. It is packaged in a moisture proof bag and sold in aliquots good for 100 reactions per vial. The offering price will be $100 per vial, and each vial will cost the company 5 cents each to produce. The company has applied for the trademark designation and the patent process for this discovery is ongoing.
Dont forget its not just customers their losing BUT also Gov. Grants, OUTCH - That one hurt.LOL
jcryan19,Very good point.You know Tony said if the deal is good enought for everyone he would take it.When a Big comp. and or Lab is loseing Millions to Dnap and them knowing whats ahead with the Statnomes/Ovarian you can see how they would have no problems giving Tony a Blank Check. A Big Lab would be able to put out 10 times the work load with OUR Products under their belts and make 10 Times the money coming in.The customer base will already be there either way you look at it, WE WIN.
Retro, oh yes ! think about just how many people and comp.'s will be POed. The loss in customer base will be astounding. Dnap simply has a much better product at the same cost and in some cases cheaper. Every month we grow in Validation by the end of the year there will be a whole list of cases Dnap will be doing work with. And in the middle of All this validation comes Eye color and Hair color, Picture it. Now More and more cases come in, more validation after validation and Bang it becomes Very clear to everyone there simply is no other place to go but to Dnap.What everyone is waiting for is eye and hair to come out.This could easy turn into a legal thing, a big legal matter if a agency doesn't go to Dnap. Agencys and people could catch a lot of HEAT for not using Dnap. Think about it. Either way we win.
Its a HOT Summer Day,very Hot.You see 2 kids selling coolaid you walk over to get some. You see Both are about the same price But one has Bigger Cups and lots of ice the other does not.1} Who you going to buy from ? and 2}What will happen to the one who gets no sales. 3} what are his choises ?
The one who gets no sales can 1} Close shop; 2} Beat the other kid up; 3} Buy him Out; 4} Merg - pooling their resources.
So whats The Point ????
When Dnap come out with DnaWitness 2.5 + Eye Color + Hair Color and profile, why would anyone go anywhere else for work to be done on DNA.Everyone will feel the sting,in the pocket, as in 50% to 80% revenue loss for most Labs around the country in every state they will be loseing customers in droves.Get it. They will be going out of business or for the Bigger Labs they can, if their smart, offer Tony a very very very nice deal. The one with the best offer will get it. You see its all about money. Once they see the DROP in revenue and customers they will be coming to Tony not the other way around and they will do it very fast.No one is going to risk their job by having work done on Dna with little or no return for the dollar.
Come on Tony !!! You been working on Retinome {TM}-HA,{hair color} as long as you been with EYE color.Let the NEWs out on BOTH at the same time. You can do it Tony.
Reto, very interesting, i didn;t know about his post.
If some one can find info. on "Trade Marks" for Dnap and post it here that would be a great help.So far I've found nothing and thats not a good sign.
Retro,all dnap's trade mark's are expired in the trade Mark office, all of them. That is Dnaprint {TM};TruseQ{TM};SnipScan{TM};TruSpin{TM};SnipDoc{TM};DNACorporate{TM};DNAGenealogy{TM};DNADATING{TM}: All listed in the 11-6-200, 8-K12G3 Filing.
Reply, if not Frudakis than someone very ,very close to him.
retro,all info on patents I got from the US patent office web site.On Patent app. Status search.
Posts from - Stockpimpdaddy - 274204 {see below},274209,274308,274314. At raging Bull.
I have the scoop
straight from the horses mouth. Company decided to reduce dependence on H1 employees several months ago, in part because all but a couple of the H1 employees were unproductive. Fruda wanted to get younger, harder working genius types rather than older, slower, unmotivated types with lots of letters behind their names because he can work and mold the former much better to innovate. Rather than fire the older Indians, he took another, gentler approach, which worked as most of them left on their own. Venkat was the only one that wouldn't go - couldnt get a job anywhere else as everyone rejected his application - and the Company was going to have to be more direct about it (let him go) but is very happy he finally got the message and resigned cause that saves company workers comp. Also Fruda didnt let him go prior because he is probably too nice a guy and didnt want to hurt his family. He kept giving him chances to perform but Richard is not a nice guy, he is sort of the opposite, and it is no coincidence that Venkat left soon after Richard became CEO.
It turns out the two young Indian programmers that remain, Visu and Shiva, are the only one of the original Indian mathematicians that Fruda values contribution from. That is because they are the only ones that can JAVA program, and because they are energetic. Its a performance issue plain and simple - Fruda and company demand extreme performance, it was not forthcoming, and those that did not provide it are now gone, with new people that are younger, more energetic and frankly, smarter replacing them.
The entire company was pissed at Venkat because he never wrote any original programs - he could do nothing without Visu and Shiva. He never thought creatively. His biggest legacy - his most significant accomplishment during his whole time at DNAP was setting up the companys library according to horse. When the algorithm for the ancestry test showed a flaw back in the early development days of that test, he said he would have thought his vaunted stat geneticist would have figured it out. Instead it was his biologist lab techs and Visu (who wrote the program) that figured it out. Why? The biologists and the young, energetic programmer apparently cared so much about the company and the test that he spent the time suffering to figure out the problem. This was his biggest example of why he didnt value Venkat. Turns out Venkats problems were that he was
1) lazy - got into the office at 10 in the morning, never worked weekends like the others, was gone for entire afternoons or several hours in the middle of the morning. Some of the worst work habits horse has ever seen. The story he gave of the company techs caring enough about company to find the flaw in the ancestry test program applies here because this is also a matter of effort and desire, or should we say lack of it on Venkats part. venkat was too lazy to get in there and get his hands dirty. This is only one of the examples he gave me - cant remember the others.
2) Incompetent - the only statistical genetics skill he had was downloading third party programs. This is not a crime, but for a stat geneticist hired towrite original software, this is a big problem. He never developed one program on his own, and not an innovative bone in his body. ALL of company's innovative programming was done by the two Indians that remain (Visu and Shiva), under Tonys Chandras and Mark Shrivers guidance - which incidentally is why they remain. Chandra was the best of them pushed out but his experience was not specialized enough in the field of genetics. Fruda wanted young energetic genius types to replace them.
3) emotionally unstable - he and staff got along fine but all considered him emotionally unstable. Mch like the Korean guy was from before. Very prone to emotional discourse - which is pretty strange for a scientist.
4) unwanted - Most lab techs had been asking for CEO to let him go for quite a while but Fruda resisted, being too nice a guy.
5) Unwise and inexperienced - he brought in people that could not contribute or perform at a high level, though most of these folks are good people and eveyone liked them.
Replacing Venkat is an expert with neural networks they got from New College - a young genius type that didnt need school but only went to school because he had to in order to fit into the professional world. He works there full time now - company does not release PRs on new non-management hires anymore, which is why you havent heard about him. This is a definite upgrade from Venkat. He is building new artificial machine learning programs to help the company further innovate and is currently working on the eye color validation project which he says will produce greater than 95% cross validation accuracy with the injection of new ancestry related markers to the mix. This guy writes his own software, not just download from the net like Venkat and he has already dramatically improved the companys eye color product. They are also going to be bringing in at least one Russian programmer to help the other two, and will be establishing a full time employee at what he says is the worlds formemost lab for the type of genetics research they do based on ancestry to replace Chandra with more relevant and focused experience.
Bottom line is horse feels the company is much stronger, leaner, efficient, and effective now, that it certainly has more financial stability (money in bank) and that it should do its first $1M year this year (two more quarters to go). He laughed when this guy was compared to the Korean guy - who was totally useless and was also discarded. Reason he laughed is Company got rid of both in almost exactly the same way - pushed them to a point where they resigned rather than firing them (much better for company). He said that if a person is good and productive, company wants to make them happy. Its a Darwinian thing - some live to reproduce and become successful and some die off ... If a person is good but cant function creatively or independently - they will get rid of them. If they just plain suck even though their resume looked good - they will get rid of them. Only the best can stay and everyone at that company including Frudakis himself are held to very high performance standards. Reaction after Korean guy left was similar - yet he pointed out the great success the company has had since then - becoming the first company in history to use a genomics product for some measurable social good - in this case solving a serial killer case. Venkat was not involved in any of that work - and that was indicative of the problem. He sat in his office reading journal articles and magazines all day, sometimes giving senseless, nonsensical jobs to the company programmers, none of which ever led to anything useful for the company (like comparing old style DNA profiles he called STRs across US States - ridiculuous and pointless). Just like the Korean guys departure was good for the company, so too will this one be. According to horse, everyone in the company is really stoked to finally be rid of the final wart on what is becoming an otherwise pretty face.
Patents on ave. take about 45 to 55 steps of processing for patent approval. Of the patents listed on Dnap web site that are listed on the US patent web site there is only one that is around step 28 - 50% of the way through patent approval and it was filed in 2001.The rest, most filed in 2002 and ave around steps 10 or 11 of the 45 to 55 steps to complete.We have a long way to go just for patent approval.
The 7 that are in valid are :
02/38309
02/41465
02/16789
60/140363
60/404357
60/467613
and their may be others.